Mayo Foundation for Medical Education and Research

Duke University

Children's Hospital Research Center at Oakland

Ixcela, Inc.

Lipomics Technologies, Inc.

Richard M Weinshilboum

Eric D Wieben

Bianca A Thomae

Araba A Adjei

Liewei Wang

Thomas C Wood

Oreste Salavaggione

Linda L Pelleymounter

Zhenhua Xu

Ibrahim A Aksoy

Robert R Freimuth

Rima Kaddurah-Daouk

Baidehi Mukherjee

Yuan Ji

Diane M Otterness

John F O'Brien

Jean M Lacey

Mark J Magera

Wayne R Matson

Ronald M Krauss

Matthew P Goetz

Stephen N Thibodeau

Judy C Boughey

Michiaki Kubo

K Ranga Rama Krishnan

Rebecca Ann Baillie

Steven M Watkins

Taisei Mushiroda

Vera J Suman

Josefa Coronel

Bruce Eckloff

Joanna Biernacka

Daniel Schaid

Cynthia X Ma

Michelle M Wiest

Eric O Wieben

Madhumita Patnaik

Raymond E Galinsky

Herb M Lachman

Tanda T Dudenkov

Stephen Liggett

Lan Yan

Balmiki Ray

Mark Frye

James N Ingle

Rebecca B Raftogianis

Junmei Cairns

Ronald Honchel

Carol L Szumlanski

Krishna R Kalari

Scott J Hebbring

Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.

Modulating the aryl hydrocarbon receptor system to treat major depressive disorder

This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A&#x2192;G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.

Methods and materials for treating estrogen receptor positive breast cancer

This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.

Methods and materials for assessing chemotherapy responsiveness and treating cancer

The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.

Lipidomic approaches to determining drug response phenotypes in cardiovascular disease

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.

Sulfotransferase 1E1 sequence variants

Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.

HSD3B1 sequence variants

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are sulfotransferase allozymes. Methods for determining the sulfonator status of a subject also are described. In addition, methods for predicting the therapeutic efficacy of a compound in a subject are described, as are methods for estimating the dose of a compound to be administered to a subject.

Sulfotransferase 2B1 pharmacogenetics

Isolated sulfotransferase 1A3 nucleic acid molecules and polypeptides that include nucleotide sequence variants and amino acid sequence variants are described. Methods for determining predisposition to particular clinical conditions and methods for determining sulfonator status also are described.

Sulfotransferase 1A3 sequence variants

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to thyroid disease or cancer also are described.

Sulfotransferase sequence variants

This document provides methods and materials related to rapid, quantitative determination of TPMT activity in biological samples. Also featured are compositions and kits useful for determination of TPMT activity in biological samples.

Kit for rapid determination of thiopurine methyltransferase activity

Methods are described for determining sulfonator status of a patient and determining dosages of drugs based on copy number of the SULT1A1 gene.

Alterations in the copy number of the SULT1A1 gene

Isolated GSTO2 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as GSTO2 allozymes. Methods for determining if a subject contains a GSTO2 sequence variant also are described.

Glutathione S-transferase sequence variants

Growing community of inventors

Rochester, MN, United States of America

Richard M Weinshilboum